Skip to content
  • There are no suggestions because the search field is empty.

What detection limits are required for pharmaceutical nitrosamines?

 

Pharmaceutical nitrosamine limits are set based on acceptable daily intake (AI) values. The framework comes from ICH M7, which classifies nitrosamines as cohort of concern compounds and sets compound-specific AI limits based on carcinogenic potency data.

How limits are calculated

Each nitrosamine has an AI value expressed in nanograms per day. For example, NDMA has an AI of 96 ng/day. To convert that into a concentration limit for a specific drug product, you divide the AI by the maximum daily dose of the drug.

If a patient takes 2 g of a drug per day, and the NDMA limit is 96 ng/day, the concentration limit in the drug substance is 48 ppb (96 ng divided by 2 g). For a drug taken at 100 mg per day, the same AI gives a limit of 960 ppb.

This means the detection limit your analytical method needs to achieve depends on the drug and its dosing. High-dose drugs require lower concentration limits and therefore more sensitive methods.

Common AI values

NDMA: 96 ng/day. NDEA: 26.5 ng/day. NMBA: 96 ng/day. NDIPA: 26.5 ng/day. NEIPA: 26.5 ng/day. NDELA: currently under review with interim limits applied.

For nitrosamines without compound-specific data, a default AI of 18 ng/day applies as a conservative threshold.

What this means for your method

In practice, pharmaceutical nitrosamine testing methods need to detect at or below the concentration limits that result from these AI calculations. For high-dose APIs, that often means detection at single-digit ppb levels or lower.

GC-TEA achieves sensitivity below 2 pg N/sec, which is well within the range needed for pharmaceutical compliance testing. The ATNA provides screening sensitivity below 1 ppb for total nitrosamine content, making it suitable for early-stage screening and excipient checks.

Regulatory context

ICH M7 guidance applies globally and has been adopted by the FDA, EMA, and other regulatory bodies. Manufacturers are required to assess nitrosamine risk, implement controls, and test products against the applicable limits. This applies to both new and existing marketed products.

If you need to set up pharmaceutical nitrosamine testing, get in touch and we can advise on the right analytical approach for your specific products and dose levels.